NephroGenex (NASDAQ: NRX) and Parnell Pharmaceuticals Holdings (NASDAQ:PARN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
This table compares NephroGenex and Parnell Pharmaceuticals Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-151.70%||-134.28%||-53.60%|
Volatility and Risk
NephroGenex has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals Holdings has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Institutional & Insider Ownership
16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares NephroGenex and Parnell Pharmaceuticals Holdings’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||($1.28)||-0.47|
Parnell Pharmaceuticals Holdings is trading at a lower price-to-earnings ratio than NephroGenex, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for NephroGenex and Parnell Pharmaceuticals Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
NephroGenex presently has a consensus target price of $17.50, suggesting a potential upside of 12,400.00%. Given NephroGenex’s higher possible upside, research analysts plainly believe NephroGenex is more favorable than Parnell Pharmaceuticals Holdings.
Parnell Pharmaceuticals Holdings beats NephroGenex on 5 of the 8 factors compared between the two stocks.
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
About Parnell Pharmaceuticals Holdings
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Receive News & Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.